Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 23581433)

1.

Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.

Calderon Cabrera C, de la Cruz Vicente F, Marín-Niebla A, Carrillo Cruz E, Rios Herranz E, Espigado Tocino I, Prats Martín C, Falantes JF, Martino Galiana ML, Perez-Simón JA.

Br J Haematol. 2013 Jul;162(1):130-2. doi: 10.1111/bjh.12320. Epub 2013 Apr 13. No abstract available.

PMID:
23581433
2.

Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.

Foss FM, Ihde DC, Breneman DL, Phelps RM, Fischmann AB, Schechter GP, Linnoila I, Breneman JC, Cotelingam JD, Ghosh BC, et al.

J Clin Oncol. 1992 Dec;10(12):1907-13.

PMID:
1453206
3.

Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.

Bouwhuis SA, Davis MD, el-Azhary RA, McEvoy MT, Gibson LE, Knudsen JM, Kist JM, Pittelkow MR.

J Am Acad Dermatol. 2005 Jun;52(6):991-6.

PMID:
15928617
4.

Bexarotene therapy for mycosis fungoides and Sézary syndrome.

Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ.

Br J Dermatol. 2009 Jun;160(6):1299-307. doi: 10.1111/j.1365-2133.2009.09037.x. Epub 2009 Feb 16.

PMID:
19222457
6.

State of the art therapy of mycosis fungoides and Sézary syndrome.

Kemme DJ, Bunn PA Jr.

Oncology (Williston Park). 1992 Feb;6(2):31-42; discussion 44, 47-8. Review. Erratum in: Oncology (Huntingt) 1992 Aug;6(8):41.

PMID:
1532501
7.

Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.

Tsirigotis P, Pappa V, Papageorgiou S, Kapsimali V, Giannopoulou V, Kaitsa I, Girkas K, Papageorgiou E, Stavrianeas N, Economopoulos T, Dervenoulas J.

Br J Dermatol. 2007 Jun;156(6):1379-81. Epub 2007 Apr 25. No abstract available.

PMID:
17459033
8.

Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.

Avilés A, Nambo MJ, Neri N, Castañeda C, Cleto S, Gonzalez M, Huerta-Guzmán J.

Cancer Biother Radiopharm. 2007 Dec;22(6):836-40.

PMID:
18158775
9.

Pentostatin (2'-deoxycoformycin) for the treatment of lymphoid neoplasms.

Ho AD, Thaler J, Willemze R, Lauria F, Mandelli F, Stryckmans P, de Cataldo F, Baccarani M, Peetermans ME, de Witte T, et al.

Cancer Treat Rev. 1990 Sep;17(2-3):213-5. No abstract available.

PMID:
2272036
10.

Sézary syndrome in an 11-year-old girl.

Meister L, Duarte AM, Davis J, Perez JL, Schachner LA.

J Am Acad Dermatol. 1993 Jan;28(1):93-5.

PMID:
8425978
11.

Pentostatin treatment of cutaneous T-cell lymphoma.

Dearden C, Matutes E, Catovsky D.

Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):37-40.

12.

Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.

Ho AD, Suciu S, Stryckmans P, De Cataldo F, Willemze R, Thaler J, Peetermans M, Döhner H, Solbu G, Dardenne M, Zittoun R.

Semin Oncol. 2000 Apr;27(2 Suppl 5):52-7.

PMID:
10877053
13.

The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.

Sanli H, Akay BN, Anadolu R, Ozcan M, Saral S, Akyol A.

J Drugs Dermatol. 2011 Apr;10(4):403-8.

PMID:
21455551
14.

Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.

Molin L, Thomsen K, Volden G, Aronsson A, Hammar H, Hellbe L, Wantzin GL, Roupe G.

Acta Derm Venereol. 1987;67(3):232-6.

PMID:
2442936
15.

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.

Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbé C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM.

Eur J Cancer. 2013 Jan;49(2):386-94. doi: 10.1016/j.ejca.2012.08.017. Epub 2012 Sep 13.

PMID:
22981498
16.

Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.

Talpur R, Thompson A, Gangar P, Duvic M.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):297-304. doi: 10.1016/j.clml.2014.01.010. Epub 2014 Feb 4.

PMID:
24589156
17.

Chemotherapy for mycosis fungoides and the Sézary syndrome.

Rosen ST, Foss FM.

Hematol Oncol Clin North Am. 1995 Oct;9(5):1109-16. Review.

PMID:
8522487
18.

A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.

Scarisbrick JJ, Child FJ, Clift A, Sabroe R, Whittaker SJ, Spittle M, Russell-Jones R.

Br J Dermatol. 2001 May;144(5):1010-5.

PMID:
11359390
19.

Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.

Capalbo S, Delia M, Dargenio M, Liso A, Diomede D, Garofalo L, Liso V.

Med Oncol. 2003;20(4):389-96.

PMID:
14716037
20.

The use of amitriptyline in mycosis fungoides.

Coe P.

Palliat Med. 1999 May;13(3):264. No abstract available.

PMID:
10474718
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk